Related Experiment Video

Updated: Jun 2, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Arachidonic acid pathway: A molecular target in human testicular cancer (Review)

Masahide Matsuyama1, Rikio Yoshimura

  • 1Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Molecular Medicine Reports
|April 9, 2011
PubMed

Insights

Non-steroidal anti-inflammatory drugs (NSAIDs) may impact cancer by targeting cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. This review explores their role in testicular cancer and the effects of related inhibitors and ligands.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are known to reduce colorectal carcinoma incidence.
  • Cyclooxygenase (COX) and lipoxygenase (LOX) enzymes are involved in prostaglandin and leukotriene production, respectively, and may play roles in carcinogenesis.
  • Peroxisome proliferator activator-receptor (PPAR)-γ is a transcriptional factor involved in adipocyte differentiation and carcinogenesis, and is modulated by NSAIDs.

Purpose of the Study:

  • To investigate the expression of COX-2, LOX, and PPAR-γ in human testicular cancer tissues.
  • To examine the effects of COX-2 and LOX inhibitors on testicular cancer.
  • To evaluate the impact of PPAR-γ ligands on testicular cancer cell growth.

Main Methods:

  • Analysis of COX-2, LOX, and PPAR-γ expression in human testicular cancer samples.
  • In vitro studies using COX-2 and LOX inhibitors.
  • Studies involving PPAR-γ ligands to assess their effects on cancer cells.

Main Results:

  • Expression levels of COX-2, LOX, and PPAR-γ were reported in human testicular cancer tissues.
  • The effects of specific inhibitors and ligands on cancer cell behavior were observed and analyzed.

Conclusions:

  • COX-2, LOX, and PPAR-γ are expressed in testicular cancer and represent potential therapeutic targets.
  • NSAIDs and related compounds modulating these pathways may offer novel strategies for testicular cancer treatment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...